216 results about "Vein injection" patented technology

Kits, apparatus, devices and methods for treating varicose veins caused by an incompetent venous junction (e.g., the saphenofemoral and / or saphenopopliteal junctions) are disclosed. The kits may include a sheath, a vein closure device, and an injection device. Alternatively, a vein closure device may include an integral injection channel and injection device. Methods may include injecting a vein with a sclerosing agent through a needle that extends in a direction that is not aligned with a longitudinal axis of a sheath or shaft.

An improved injection site (12) for infusion of parenteral fluids and the like is provided, having a pressure-actuated valve (20) and a novel split septum unit (24), which effectively prevent reflux of blood into the assembly (10). The septum unit (24) includes a resilient split septum body (64) which is precompressed so that the septum body (64) is caused to protrude proximally (78) upon insertion of a cannula (16). Consequently, upon removal of the cannula (16), there is essentially no “drumming” or creation of friction-induced negative pressures sufficient to generate blood reflux. The preloaded septum body (64) also has its proximal surface (74) essentially flush and coplanar with the adjacent proximal end (66b) of the tubular septum holder (66) to enhance the cleanliness of the unit (24). The specialized well (46) and septum unit (24) afford a resilient seal between the periphery of the septum body (64) and the surface (50), and a separate hard-surface seal between the outer margin of the surface (50) and the septum holder (66).

Apparatus and methodology are disclosed for entrapping a used intravenous needle in a needle trap and removing the needle and the trap from a catheter tube so as to avoid risk of injury to both the patient and the medical attendant.

An improved injection site (12) for infusion of parenteral fluids and the like is provided, having a pressure-actuated valve (20) and a novel split septum unit (24), which effectively prevent reflux of blood into the assembly (10). The septum unit (24) includes a resilient split septum body (64) which is precompressed so that the septum body (64) is caused to protrude proximally (78) upon insertion of a cannula (16). Consequently, upon removal of the cannula (16), there is essentially no “drumming” or creation of friction-induced negative pressures sufficient to generate blood reflux. The preloaded septum body (64) also has its proximal surface (74) essentially flush and coplanar with the adjacent proximal end (66b) of the tubular septum holder (66) to enhance the cleanliness of the unit (24). The specialized well (46) and septum unit (24) afford a resilient seal between the periphery of the septum body (64) and the surface (50), and a separate hard-surface seal between the outer margin of the surface (50) and the septum holder (66).

An intravenous injection site having a split septum assembly interfit with the site for the intravenous administration of fluids to a patient. The split septum assembly has a resilient and compressible split septum having an axially-formed slit for receipt of a blunt cannula, needle, or other medical device through said slit, a septum holder for receipt of the split septum, and a septum housing for receipt of the combined septum holder and split septum. The septum includes a body and a flange extending radially from the body. A projection extends from the flange. The septum is mounted within the septum holder, and the septum holder is mounted within the septum housing to provide axial compression of the flange. This axial compression presents a double hermetic seal that significantly minimizes or prevents proximal leakage of fluid through the slit or around the septum holder when the cannula is removed.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the novel medical usage of icaritin, in particular to the usage of icaritin in preparation of medicine for preventing and treating endotoxemia. Lipopolysaccharide (LPS) is used for stimulating the macrophage system RAW264.7 of a mouse and establishing an extraneous endotoxic inflammation model, LPS is used for stimulating the C57BL / 6J mouse and establishing the endotoxemia animal model, icaritin is adopted for intervention, and dexamethasone is used as reference. The experiment result shows that the icaritin can reduce the death rate, the level of the inflammatory factor, the inflammatory mediator and the adhesion molecules and infiltration of inflammatory cells of the tissue after the mouse is attacked by endotoxin, and proves that the icaritin can effectively prevent and treat endotoxemia and can be used for further preparing effective drug for preventing and treating endotoxemia, including dosage forms such as oral and enteric capsules or intravenous injections.

In a method and apparatus for contrast-enhanced magnetic resonance (MR) angiography of the right coronary artery of a patient, a bolus of MR contrast agent is selected to have a size that will cause the bolus, after injection into the patient, to wash out of right coronary chambers of the heart while still enhancing MR signals from the right coronary artery. The bolus of MR contrast agent is injected into the patient, and MR signals are generated in, and MR signals are obtained from, the patient in a time window after the bolus has washed out of the right coronary chambers and still enhances MR signals in the right coronary artery. An MR image of the right coronary artery is generated using only the MR signals obtained in the time window.

The invention relates to a device for intravenous injection of a mouse tail and superficial intravenous injection of other parts. The device comprises a base, a transparent tube, a front fixing part and a rear fixing part, wherein a notch is formed in the rear fixing part, and ventilation holes are formed in two side edges of the transparent tube; the base is a closed cavity with a light source inside, the base comprises a top plate, a soleplate and four side plates, an adjustable light-transmitting operation panel which is hinged to the top plate is arranged between the side plate facing one end of the tail part of a mouse and the top plate, the side edge of the top plate is provided with a fixing plate facing the interior of the base, the adjustable light-transmitting operation panel is provided with an angle adjusting screw for adjusting an angle between the adjustable light-transmitting operation panel and the fixing plate, and other three side edges of the adjustable light-transmitting operation panel are respectively provided with an elastic light screening plate which is connected to the side edge of the adjacent base. By adopting the device, the safety of the operator is adequately guaranteed, and the operator can be prevented from being bitten by the mouse when in injection; moreover, the mouse is firmly fixed, the stress response of the mouse can be prevented from affecting the experiment result, and the experiment result is more reliable.

I.V. catheter assembly was a catheter with a distal needle for insertion into a blood vessel a portion of the catheter. An adapter with a self-sealing or self-closing plug is connected to the catheter, proximally of the distal needle. A proximal needle that can couple to the distal needle is in a guard tube on the other side of the plug. In use the proximal needle is pushed through the plug and into coupling engagement with the distal needle so the distal needle can be inserted into a blood vessel. The coupled needles are then withdrawn and shielded in the guard tube. The guard tube is then disconnected from the adapter and the adapter can be used to discharge blood from, or supply fluid to the blood vessel.

Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field. The low volume, safe for injection formulations of dantrolene, as well as other formulations of dantrolene, have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.